Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA

Defilade Capital Management L.P. raised its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 21.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,504,536 shares of the company’s stock after purchasing an additional 269,902 shares during the period. Olema Pharmaceuticals accounts for about 3.1% of Defilade Capital Management L.P.’s holdings, making the stock its 14th biggest position. Defilade Capital Management L.P. owned 1.72% of Olema Pharmaceuticals worth $22,433,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of OLMA. EverSource Wealth Advisors LLC lifted its stake in shares of Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC bought a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $44,000. Russell Investments Group Ltd. purchased a new position in Olema Pharmaceuticals in the 3rd quarter valued at approximately $53,000. American Century Companies Inc. purchased a new position in Olema Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Creative Planning bought a new stake in Olema Pharmaceuticals during the 2nd quarter valued at $83,000. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

OLMA has been the topic of several recent research reports. Wall Street Zen downgraded Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Guggenheim decreased their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Price Performance

OLMA opened at $11.45 on Monday. The company has a fifty day moving average price of $11.42 and a 200-day moving average price of $16.45. The firm has a market capitalization of $1.00 billion, a P/E ratio of -5.67 and a beta of 2.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. Olema Pharmaceuticals, Inc. has a one year low of $4.47 and a one year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Equities research analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the firm’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the sale, the director owned 715,270 shares of the company’s stock, valued at $8,282,826.60. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.56% of the stock is owned by corporate insiders.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.